TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00827879

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Strength at Home Couples Group
Description: A multiple site randomized trial will compare 10 sessions of PF-RET to 10 sessions of a supportive group therapy. PF-RET focuses on 1) deployment stress and traumatic experiences impacting intimate relationships; 2) communication between intimate partners; 3) conflict and anger management; and 4) closeness and intimacy.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Supportive Group Therapy
Description: A general support group designed to enhance support for healthy relationship building.
Study: NCT01722240

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Liraglutide 1.8mg

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT01518920

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: PF-04958242 0.35 mg oral solution

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: PF-04958242 0.27 mg oral solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo oral solution
Study: NCT02653560

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium chloride powder

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium magnesium Citrate (KMgCit)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Potassium citrate powder

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00721773

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril
Description: Patients with hypertension will take 10-20mg benazepril per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valsartan
Description: Patients with hypertension will take 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benazepril+Valsartan
Description: Patients with hypertension will take 10-20mg benazepril plus 80-160mg valsartan per day, antihypertensive agents other than ACE inhibitors and ARBs will be allowed. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Control
Description: Patients in the control group will administer antihypertensive agents, except ACE inhibitors and ARBs. Doses are adjusted appropriately to achieve and maintain the target blood pressure of 120-140/70-90 mmHg.
Study: NCT01894581

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: LOVAZA
Description: Subjects will be instructed to take 2 grams twice daily of oral omega-3-acid ethyl esters (Lovaza) starting with day 1 to 3 of their menstrual period. Each capsule contains 60mg of other omega-3 FA. On day 1 of their subsequent menstrual period, subjects will be instructed to discontinue.

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: LOVAZA
Description: Subjects will be instructed to take 2 grams twice daily of oral omega-3-acid ethyl esters (Lovaza) starting with day 1 to 3 of their menstrual period. Each capsule contains 60mg of other omega-3 FA. On day 1 of their subsequent menstrual period, subjects will be instructed to discontinue.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GnRH
Description: An intravenous bolus of exogenous GnRH (75 ng/kg dosing based on total body weight) will be administered at 6 hours.
Study: NCT03417700

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: training with placebo

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: HICT
Description: Training and vitamin D
Study: NCT01219127

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Derma-PACE
Description: ESWT group received derma-PACE shockwave treatment 2 x 1 wk for 3 wks for a total of 6 treatment using derma-PACE dervice (Alpharetta, GA). HBO groups received HBOT daily 5 days a week for 8 weeks or a total of 40 treatments.
Study: NCT01840722

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: MI-based HIV Risk Reduction
Description: As the only MI-based intervention identified by the CDC as a best-practice model, the MI-HIV intervention has been shown to demonstrate positive outcomes for criminal justice-involved women randomly assigned to the intervention group for risky sexual activity and drug use with sustained behaviors through 9 months.
Study: NCT03080350

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl sublingual
Description: Fentanyl sublingual
Study: NCT01894581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GnRH
Description: An intravenous bolus of exogenous GnRH (75 ng/kg dosing based on total body weight) will be administered at 6 hours.
Study: NCT02367677

Intervention type: OTHER
Intervention: Method comparison

Intervention type: OTHER
Intervention: Method comparison

Intervention type: OTHER
Intervention: Method comparison
Study: NCT01334268

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Taxus Liberte Paclitaxel-Eluting Coronary Stent System
Description: Taxus Liberte Paclitaxel-Eluting Coronary Stent System Implantation

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Resolute Zotarolimus-Eluting Coronary Stent System
Description: Resolute Zotarolimus-Eluting Coronary Stent System Implantation
Study: NCT00121550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: clarithromycin

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: clarithromycin
Study: NCT04138420

Intervention type: DRUG
Intervention: Bevacizumab Injection
Description: Three monthly intravitreal injections of bevacizumab (1.25 mg/0.05 mL)
Study: NCT02941445

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin and metformin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Study: NCT02201654

Intervention type: OTHER
Group type: OTHER
Intervention: EBUS without stylet
Description: the patient will receive both conventional ebus with the stylet and experimental ebus (without the stylet). The two techniques will then be compared to each other on a per lymph node basis.
Study: NCT01968590

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: DDrops(trademark) prepared two sets of bottles, one set has 300IU per metered dose and the other set has 2,000IU per metered dose. Participants are randomized to either 600 IU or 4,000 IU, and they take two measured drops orally, once a day. There is a dropper that automatically drops out a measured amount when the bottle is turned upside down.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Description: DDrops(trademark) prepared two sets of bottles, one set has 300IU per metered dose and the other set has 2,000IU per metered dose. Participants are randomized to either 600 IU or 4,000 IU, and they take two measured drops orally, once a day. There is a dropper that automatically drops out a measured amount when the bottle is turned upside down.
Study: NCT01988259

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Bilateral approach for Laminoplasty
Description: Open bilateral approach for laminoplasty in multilevel cervical spinal stenosis

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Unilateral approach for laminoplasty
Description: Unilateral minimally invasive approach for laminoplasty in multilevel cervical spinal stenosis.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Subperiosteal approach for foraminotomy
Description: Unilateral subperiostal approach for single level foraminotomy

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Transmuscular approach for foraminotomy
Description: Unilateral transmuscular approach for single level foraminotomy
Study: NCT03712319

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: REM Volver a casa
Description: The program aims to train the ability of the mind to focus attention on the present moment without judging, accepting the experience. REM is an application available for Android and iOs. It proposes a guided training through 8 stages. They contain video recordings with explanations about the fundamentals of mindfulness, audio recordings that guide practices of mindfulness, as well as suggestions to bring it into everyday life. They can be used whenever it suits the user. The app counts the progress of each participant, as well as the mood changes according to a distress scale before and after performing a formal practice. The app has been designed following the international recommendations for the development of apps (MARS guide).

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness-Based Stress Reduction program
Description: The program aims to train the ability of the mind to focus attention on the present moment without judging, accepting the experience. MBSR is a program developed at the University of Massachusetts Medical Center in the 1970s by Professor Jon Kabat-Zinn. MBSR uses a combination of mindfulness meditation, body awareness, and yoga to help people become more mindful. In recent years, meditation has been the subject of clinical research, that suggests it may have beneficial effects, including stress reduction, relaxation, and improvements to quality of life. While MBSR has its roots in spiritual teachings, the program itself is secular. The session is delivered to a small group of people by a certified instructor during two and a half hours, every week.
Study: NCT01759030

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Patients will will receive rituximab a dose of 1000 mg , intravenously, slowly, once in 2 weeks, with 2 infusions per course (on day 1 and day 15).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rituximab
Description: Patients will will receive rituximab a dose of 1000 mg , intravenously, slowly, once in 2 weeks, with 2 infusions per course (on day 1 and day 15).
Study: NCT02213016

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transcranial Magnetic Stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham Transcranial Magnetic Stimulation
Study: NCT00289315

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary (Environmental) Weight Gain Prevention
Description: School-based program that modifies the school environment to promote healthy eating and physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Primary (Environmental) Weight Gain Prevention
Description: School-based program that modifies the school environment to promote healthy eating and physical activity

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Secondary (Behavioral) Weight Gain Prevention
Description: School-based environmental program to promote healthy eating and physical activity in the overweight students.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Control
Description: Control program that does not include an active intervention for promoting healthy eating and physical activity.
Study: NCT03376854

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hypothermia
Description: Subjects will be cooled using either cooling blankets or gel-pad systems to maintain core temperature 34-35°C.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Neuromuscular Blocking Agents
Description: Subjects in the TH + NMB arm will be deeply sedated using agents at the discretion of the primary ICU team, then start continuous iv infusion of either cisatracurium, atracurium, or vecuronium titrated to 2 twitches on train of four monitoring and further titrated to ablate visible shivering.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care
Description: Subjects who are hypothermic (≤36°C) during CRRT will receive surface warming to restore core temperature to 37°C. Patients with core temperature \>38°C will receive 650 mg acetaminophen and, if temperature remains \>38°C, surface cooling will be initiated to return core temperature to 37-38°C.
Study: NCT00463346

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acamprosate
Description: Acamprosate 1998 mg tid

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study: NCT01238679

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PF-04958242
Description: Administered as specified in the treatment arm

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm
Study: NCT01798199

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: The training by Verve System
Study: NCT03556007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3471851
Description: LY3471851 drug product is a sterile liquid for subcutaneous injection that will be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3471851
Description: LY3471851 drug product is a sterile liquid for subcutaneous injection that will be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3471851
Description: LY3471851 drug product is a sterile liquid for subcutaneous injection that will be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY3471851
Description: LY3471851 drug product is a sterile liquid for subcutaneous injection that will be diluted with sterile 0.9% sodium chloride solution for injection (USP) prior to administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo dosing solution is 0.9% sodium chloride for injection (USP).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo dosing solution is 0.9% sodium chloride for injection (USP).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo dosing solution is 0.9% sodium chloride for injection (USP).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: The placebo dosing solution is 0.9% sodium chloride for injection (USP).
Study: NCT04407000

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Test: Favipiravir 200 mg (LOQULAR)
Description: Test Drug

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Reference: Favipiravir 200 mg (Avigan)
Description: Reference Drug
Study: NCT02144233

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Occlusal adjustment
Description: The first step consists of the elimination of premature tooth contacts during retruded jaw closure.~The second step included reduction of the steeper lateral anterior guidance; the magnitude of this alteration will be estimated by the following equation: (right condylar path) × (left anterior guidance) = (left condylar path) × (right anterior guidance)

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo occlusal adjustment
Description: Placebo occlusal adjustment will take place in a manner identical to the real adjustment. However, a specially fabricated inactive rotary instrument will be used, and no enamel will be removed.
Study: NCT03080350

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fentanyl ev
Description: Fentanyl ev

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo sublingual
Description: Placebo sublingual

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo ev
Description: Placebo - NaCL 0,9% ev
Study: NCT04069455

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Electronic Patients Reported Outcomes
Description: ePRO is a application which is web based and accessible from home or mobile device, for patients to complete symptom reports and receive severity-based advice
Study: NCT04084522

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Saturated Fat- Desi Ghee (Clarified Butter)
Description: Desi Ghee which is also known as clarified butter contains around 70% of saturated fat. in India it is one of the important culinary items which promotes longevity and protects against various diseases, attributing numerous health benefits. Ghee consumption has also significant hypolipidemic and hypocholesterolemic effects.

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Soyabean Oil
Description: Soyabean Oil consists of around 84% of unsaturated fat and is the most widely used source of unsaturated fat used in the area.
Study: NCT03905642

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arikayce™
Description: Amikacin (aminoglycoside) in a liposomal formulation.
Study: NCT03686839

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SMR neurofeedback training to MCI
Description: SMR neurofeedback training consisted to increase the synaptic strengths and sensitivity within this network. Electroencephalography signals for SMR/theta ratio training was recorded at channel Cz according to the International 10-20 system. Theta rhythm was also recorded and, in this case, SMR was stimulated while theta waves were suppressed. A 32 channels system (EEGDigitrack Biofeedback plus module, Inc Elmiko Medical) was used for SMR/theta neurofeedback training.
Study: NCT03719547

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Abdominal radical hysterectomy
Description: Radical hysterectomy (type B or C according to the Querleu\&Morrow classification) with pelvic lymphadenectomy

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Robot-assisted radical hysterectomy
Description: Radical hysterectomy (type B or C according to the Querleu\&Morrow classification) with pelvic lymphadenectomy
Study: NCT03577301

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Clinic-based Delivery
Description: A minimum of 2 community health workers (CHWs) will be trained to deliver clinic-based intervention sessions.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Remote Delivery
Description: A minimum of 2 community health workers (CHWs) will be trained to deliver intervention sessions to the participant in a location remote from the clinic setting.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Multi-modal Delivery
Description: A minimum of 2 community health workers (CHWs) will be trained to deliver clinic-based or remote intervention sessions. First MI session is in person immediately after baseline. Sessions 2-4 can be delivered in person or remotely based on youth preference.
Study: NCT03719547

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Sentinel lymph node biopsy
Description: Assessment of sentinel lymph nodes using either radiotracer or indocyanine green (ICG)

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy
Description: Assessment of sentinel lymph nodes using either radiotracer or indocyanine green (ICG)
Study: NCT01920932

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: brentuximab vedotin
Description: Given intravenously (IV).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: etoposide
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: Given orally (PO).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: doxorubicin
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dacarbazine(R)
Description: Given IV.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: filgrastim
Description: Given subcutaneously (SQ) as clinically indicated.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: quality of life assessment
Description: Quality of life assessment will be done at initial clinical visit, and during chemotherapy, completion of therapy, then at 1 year, 2 years and 5 years. It should take no more than 15-20 minutes to complete. Participation is voluntary by participating institution and by participant.

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: radiation therapy
Description: At the end of chemotherapy and recovery of blood counts, radiotherapy will be given to any involved nodes (if any) that are not in complete remission.
Study: NCT02020395

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: test meal (500 kcal)
Description: whole wheat bread (68 g), butter(10 g), ham (25 g); chocolate cream (90 g); orange juice (200 mL)

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: test meal (500 kcal)
Description: whole wheat bread (68 g), butter(10 g), ham (25 g); chocolate cream (90 g); orange juice (200 mL)
Study: NCT02389088

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Letrozole
Description: In Phase II, letrozole, 5 mg/day, will be given for 14 days
Study: NCT03472027

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-145
Description: Anti-CTLA-4 monoclonal antibody, IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-145
Description: Anti-CTLA-4 monoclonal antibody, IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-145
Description: Anti-CTLA-4 monoclonal antibody, IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-145
Description: Anti-CTLA-4 monoclonal antibody, IV infusion

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BCD-145
Description: Anti-CTLA-4 monoclonal antibody, IV infusion
Study: NCT02939235

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crushed ticagrelor followed by morphine
Description: Crushed ticagrelor (180 mg) followed by morphine 5 mg intravenously

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Crushed ticagrelor, morphine,metoclopramide
Description: Crushed ticagrelor (180 mg) orally followed by morphine 5 mg and metoclopramide 10 mg intravenously